NT-501 is under clinical development by Amgen and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NT-501’s likelihood of approval (LoA) and phase transition for Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT) took place on 08 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NT-501 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NT-501 overview

NT-501 is under development for the treatment of glaucoma and macular telangiectasia type 2 (Mactel). NT-501 is an intraocular implant. NT-501 consists of encapsulated human cells genetically modified (designated as NTC-201) to secrete ciliary neurotrophic factor (CNTF), designed to continually deliver a low, safe and therapeutic dose of CNTF into the back of the eye.

It was also under development for the treatment of geographic atrophy associated with dry atropic macular degeneration, ischemic optic neuropathy, achromatopsia, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, spinal muscular atrophies, retinitis pigmentosa, choroideremia and usher syndrome type-2 and type-3.

Amgen overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.

Quick View NT-501 LOA Data

Report Segments
  • Innovator
Drug Name
  • NT-501
Administration Pathway
  • Intraocular
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.